CardioComm Solutions Secures Health Canada Clearance for Artificial Intelligence ECG Interpretation for Multiple Cardiac Arrhythmias
CardioComm Solutions, Inc. (TSXV: EKG) has received Health Canada clearance for its GEMS™ Rhythm ECG artificial intelligence (AI) software for automated detection of multiple arrhythmias and morphology abnormalities. The software will detect conditions such as atrial fibrillation, prolonged QT intervals, tachycardia, bradycardia, and more. This clearance is a critical milestone in developing GEMS™ into an all-in-one, device-agnostic ECG software solution.
GEMS™ Rhythm will be initially offered with GEMS™ FLEX ECG software for analyzing ECG data from event recorders worn up to 30 days. Future releases will include integration with GEMS™ Holter and GEMS™ LTCM solutions for continuous monitoring over 24 hours to 14 days. The NRC Industrial Research Assistance Program provided partial funding support of up to $150,000 for this project.
CardioComm Solutions, Inc. (TSXV: EKG) ha ricevuto l'autorizzazione da Health Canada per il suo software GEMS™ Rhythm ECG basato su intelligenza artificiale (AI) per la rilevazione automatizzata di diverse aritmie e anomalie morfologiche. Il software sarà in grado di rilevare condizioni come la fibrillazione atriale, gli intervalli QT prolungati, la tachicardia, la bradicardia e altro ancora. Questa autorizzazione rappresenta un traguardo fondamentale nello sviluppo di GEMS™ come una soluzione software ECG unica e indipendente dai dispositivi.
GEMS™ Rhythm sarà inizialmente offerto insieme al software GEMS™ FLEX ECG per l'analisi dei dati ECG provenienti da registratori di eventi indossati per un massimo di 30 giorni. Le versioni future includeranno l'integrazione con le soluzioni GEMS™ Holter e GEMS™ LTCM per un monitoraggio continuo da 24 ore a 14 giorni. Il Programma di Assistenza alla Ricerca Industriale NRC ha fornito un supporto economico parziale fino a $150,000 per questo progetto.
CardioComm Solutions, Inc. (TSXV: EKG) ha recibido la autorización de Health Canada para su software GEMS™ Rhythm ECG basado en inteligencia artificial (AI) para la detección automatizada de múltiples arritmias y anomalías morfológicas. El software detectará condiciones como fibrilación auricular, intervalos QT prolongados, taquicardia, bradicardia y más. Esta autorización es un hito crítico en el desarrollo de GEMS™ como una solución de software ECG todo-en-uno y agnóstica de dispositivos.
GEMS™ Rhythm se ofrecerá inicialmente con el software GEMS™ FLEX ECG para analizar datos ECG de registradores de eventos utilizados hasta 30 días. Las futuras versiones incluirán la integración con las soluciones GEMS™ Holter y GEMS™ LTCM para monitoreo continuo durante 24 horas a 14 días. El Programa de Asistencia a la Investigación Industrial NRC proporcionó apoyo financiero parcial de hasta $150,000 para este proyecto.
CardioComm Solutions, Inc. (TSXV: EKG)는 Health Canada의 승인을 받았습니다 GEMS™ Rhythm ECG 인공지능(AI) 소프트웨어 다수의 부정맥 및 형태학적 이상을 자동으로 탐지합니다. 이 소프트웨어는 심방 세동, QT 간격 연장, 빈맥, 서맥 등의 상태를 탐지할 것입니다. 이 승인은 GEMS™를 장치 독립적인 올인원 ECG 소프트웨어 솔루션으로 개발하는 데 있어 중대한 이정표입니다.
GEMS™ Rhythm은 처음에 최대 30일 동안 착용할 수 있는 이벤트 레코더의 ECG 데이터를 분석하는 GEMS™ FLEX ECG 소프트웨어와 함께 제공됩니다. 향후 릴리스에는 24시간에서 14일 동안 지속적인 모니터링을 위한 GEMS™ Holter 및 GEMS™ LTCM 솔루션과의 통합이 포함될 것입니다. NRC 산업 연구 지원 프로그램은 이 프로젝트에 대해 최대 $150,000의 부분적인 자금 지원을 제공하였습니다.
CardioComm Solutions, Inc. (TSXV: EKG) a reçu l'autorisation de Health Canada pour son logiciel GEMS™ Rhythm ECG basé sur l'intelligence artificielle (IA) pour la détection automatisée de multiples arythmies et anomalies morphologiques. Le logiciel détectera des conditions telles que la fibrillation auriculaire, les intervalles QT prolongés, la tachycardie, la bradycardie et plus encore. Cette autorisation représente un jalon critique dans le développement de GEMS™ en tant que solution logicielle ECG tout-en-un et indépendante des dispositifs.
GEMS™ Rhythm sera initialement proposé avec le logiciel GEMS™ FLEX ECG pour analyser les données ECG provenant d'enregistreurs d'événements portés jusqu'à 30 jours. Les futures versions incluront l'intégration avec les solutions GEMS™ Holter et GEMS™ LTCM pour un suivi continu de 24 heures à 14 jours. Le Programme d'Aide à la Recherche Industrielle du NRC a fourni un soutien financier partiel allant jusqu'à 150 000 $ pour ce projet.
CardioComm Solutions, Inc. (TSXV: EKG) hat die Genehmigung von Health Canada erhalten für seine GEMS™ Rhythm ECG-Software, die auf künstlicher Intelligenz (AI) basiert, zur automatisierten Erkennung von mehreren Arrhythmien und Morphologieanomalien. Die Software wird Zustände wie Vorhofflimmern, verlängerte QT-Intervalle, Tachykardie, Bradykardie und mehr erkennen. Diese Genehmigung ist ein wichtiger Meilenstein für die Entwicklung von GEMS™ zu einer All-in-One, geräteunabhängigen ECG-Softwarelösung.
GEMS™ Rhythm wird zunächst zusammen mit der GEMS™ FLEX ECG-Software angeboten, die ECG-Daten von bis zu 30 Tage tragbaren Ereignisrekordern analysiert. Zukünftige Versionen werden die Integration mit GEMS™ Holter und GEMS™ LTCM-Lösungen für die kontinuierliche Überwachung über einen Zeitraum von 24 Stunden bis 14 Tagen umfassen. Das NRC Industrial Research Assistance Program hat für dieses Projekt finanzielle Unterstützung in Höhe von bis zu 150.000 USD bereitgestellt.
- Received Health Canada clearance for GEMS™ Rhythm ECG AI software
- Software capable of detecting multiple arrhythmias and morphology abnormalities
- Critical milestone in developing an all-in-one, device-agnostic ECG software solution
- Expanding product line to include Event, Holter/Event, and LTCM solutions
- Received up to $150,000 in research and development support from NRC-IRAP
- None.
GEMS(TM) Rhythm AI Clearance will Address Event, Holter and Long-Term Continuous ECG Monitoring Needs for Remote Patient Monitoring in Canada
Toronto, Ontario--(Newsfile Corp. - September 30, 2024) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software and hardware solutions, is pleased to announce it has received Health Canada clearance of its GEMS™ Rhythm ECG artificial intelligence (AI) software for the automated detection of multiple arrhythmias and morphology abnormalities.
The GEMS Rhythm arrhythmia and morphology abnormality AI detection will include atrial fibrillation, prolonged QT and QTc intervals, tachycardia/bradycardia/pause, average heart rate, PQ and QRS intervals, identification of patterns of different heart beats such as PACs, PVCs, bigeminy and trigemini, as well as estimation of the heart rate variability.
The clearance of the GEMS™ Rhythm technology is a critical milestone in the Company's product road map to develop its GEMS™ software into an all-in-one, device-agnostic, ECG software solution. GEMS™ Rhythm will first be offered with the Company's GEMS™ FLEX ECG software to support automated analysis of one to three leads of ECG data acquired through event recorders worn for up to 30 days. Additionally, GEMS™ Rhythm will automatically review ECGs from its consumer HeartCheck™ ECG products.
In the next phases of software releases, GEMS™ Rhythm will be used with the GEMS™ Holter and GEMS™ LTCM solutions (in development) to perform continuous monitoring of ECGs over durations of 24 hours to 14 days, with near real-time event triggering throughout the monitoring period. CardioComm's all-in-one GEMS™ solutions for Event, Holter/Event, and LTCM will provide hospitals, physician groups, and commercial laboratories with ultimate flexibility to provide customized patient care in a fully integrated, device-agnostic software solution.
GEMS™ Rhythm, GEMS Holter, and GEMS™ LTCM will join CardioComm's growing product lines, including the HeartCheckTM branded home ECG devices and the Body-by-GEMSTM multiple bio-signal monitoring solutions.
CardioComm is pleased to confirm that research and development support for this GEMS™ Rhythm project was provided in part through an NRC Industrial Research Assistance Program (NRC-IRAP) contribution agreement of up to
To learn more about CardioComm's products and for further updates please visit the Company's website at www.cardiocommsolutions.com.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 and ISO 27001 certifications, is HIPAA compliant and holds medical device clearances and sales licenses from the USA (FDA) and Canada (Health Canada).
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
investor.relations@cardiocommsolutions.com
Forward-looking statements
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/225191
FAQ
What did CardioComm Solutions (TSXV: EKGGF) receive Health Canada clearance for?
What conditions can the GEMS™ Rhythm AI software detect?
How will CardioComm Solutions (TSXV: EKGGF) initially offer the GEMS™ Rhythm software?